EMA Authorised: Orkambi (Lumacaftor;ivacaftor) — Vertex Pharmaceuticals (Ireland) Limited

View source ↗

Summary

Orkambi (lumacaftor/ivacaftor) has been authorised by EMA for cystic fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ORKAMBI (lumacaftor and ivacaftor)

Snippet

Status: Authorised. Therapeutic area: Cystic Fibrosis. MAH: Vertex Pharmaceuticals (Ireland) Limited. Decision date: 26/03/2026